The antidepressant Cymbalta® (duloxetine HCl) – a product of Eli Lilly and Company (NYSE: LLY) – has recently been approved by the USFDA for the treatment of generalized anxiety disorder (GAD) in adults (ages 18 and above).
The approval came following completion of three randomized, double-blind, placebo-controlled studies in more than 800 non-depressed adults with GAD, which established the safety and efficacy of Cymbalta®.
Already approved in the United States for the treatment of major depressive disorder and management of diabetic peripheral neuropathic pain (both in adults), Cymbalta® is a member of a class of drugs commonly known as serotonin and norepinephrine reuptake inhibitor (SNRI).
Find more details from the press release.
» FDA Approves Cymbalta for Fibromyalgia from PharmaGazette
Eli Lilly & Co. (NYSE:LLY) announced that it has received U.S. Food and Drug Administration approval for Cymbalta for the management of fibromyalgia, a chronic pain disorder.Cymbalta (duloxetine HCl) is the first serotonin-norepinephrine reupt... [Read More]
Tracked on: June 24, 2008 1:28 PM | Permalink to Trackback